Partin AW - Search Results

1

Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.

Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ 3rd, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL. Murphy GP, et al. Among authors: partin aw. Prostate. 1997 Dec 1;33(4):281-5. doi: 10.1002/(sici)1097-0045(19971201)33:4<281::aid-pros9>3.0.co;2-k. Prostate. 1997. PMID: 9397201

2

Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.

Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, deKernion JB. Marks LS, et al. Among authors: partin aw. J Urol. 1996 Sep;156(3):1035-9. J Urol. 1996. PMID: 8709302

3

Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.

Partin AW, Piantadosi S, Subong EN, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, Carter HB. Partin AW, et al. Prostate Suppl. 1996;7:35-9. Prostate Suppl. 1996. PMID: 8950362

4

Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.

Polascik TJ, Manyak MJ, Haseman MK, Gurganus RT, Rogers B, Maguire RT, Partin AW. Polascik TJ, et al. Among authors: partin aw. Cancer. 1999 Apr 1;85(7):1586-92. Cancer. 1999. PMID: 10193950 Clinical Trial.

5

Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer.

Manyak MJ, Hinkle GH, Olsen JO, Chiaccherini RP, Partin AW, Piantadosi S, Burgers JK, Texter JH, Neal CE, Libertino JA, Wright GL Jr, Maguire RT. Manyak MJ, et al. Among authors: partin aw. Urology. 1999 Dec;54(6):1058-63. doi: 10.1016/s0090-4295(99)00314-3. Urology. 1999. PMID: 10604708 Clinical Trial.

6

Report on Prostate Cancer Tumor Marker Workshop 1999.

Partin AW, Murphy GP, Brawer MK. Partin AW, et al. Cancer. 2000 Feb 15;88(4):955-63. Cancer. 2000. PMID: 10679666 No abstract available.

7

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.

Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek DJ, Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Brawer MK, et al. Among authors: partin aw. J Urol. 2000 May;163(5):1476-80. J Urol. 2000. PMID: 10751861

8

Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.

Vessella RL, Lange PH, Partin AW, Chan DW, Sokoll LJ, Sasse EA, Crawford ED. Vessella RL, et al. Among authors: partin aw. Urology. 2000 Jun;55(6):909-14. doi: 10.1016/s0090-4295(00)00461-1. Urology. 2000. PMID: 10840107 Clinical Trial.

9

Comparison of total prostate-specific antigen and derivative levels in a screening population of black, white, and Korean-American men.

Park J, Sokoll LJ, Bruzek DJ, Mangold L, Gurganus R, Khan MA, Partin AW, Chan DW, Veltri RW. Park J, et al. Among authors: partin aw. Clin Prostate Cancer. 2003 Dec;2(3):173-6. doi: 10.3816/cgc.2003.n.026. Clin Prostate Cancer. 2003. PMID: 15040861

10

Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.

Shafer MW, Mangold L, Partin AW, Haab BB. Shafer MW, et al. Among authors: partin aw. Prostate. 2007 Feb 15;67(3):255-67. doi: 10.1002/pros.20514. Prostate. 2007. PMID: 17192876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

613 results

Search Page

Filters